Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?

Figure 1 Survival of patients with mammalian target of rapamycin inhibitor vs no mammalian target of rapamycin inhibitor (survival 21. 0 ± 4.1 vs 11.2 ± 2.5 mo, P = 0.04). mTOR: Mammalian target of rapamycin.

Figure 2 Survival of patients stratified by sirolimus vs everolimus (P = 0. 88). mTOR: Mammalian target of rapamycin.

Figure 3 Survival of patients stratified by mammalian target of rapamycin inhibitor monotherapy vs combination therapy with calcineurin inhibitor (P = 0. 59). mTOR: Mammalian target of rapamycin.